Article Figures & Data
Tables
- Table 1.
Numbers of KPC-positive E. coli, K. pneumoniae, P. aeruginosa, and A. baumannii isolates among the total number of isolates and the multi-beta-lactam-resistant isolates
Organism No. of isolates No. of KPC producers/total (%) Total MβLR KPC producers All isolates MβLR isolates E. coli 4,329 219 61 61/4,329 (1.4) 61/219 (33) K. pneumoniaea 2,805 457 333 333/2,805 (12) 333/457 (73) P. aeruginosa 2,415 272 99 99/2,415 (4.1) 99/272 (44) A. baumannii 958 291 41 41/958 (4.3) 41/291 (14) Total 10,507 1,239 534 534/10,507 (5) 534/1,239 (43) ↵a P ≤ 0.05.
- Table 2.
Total numbers of hospitals, beds, and KPC-positive isolates by geographic region
Geographic region Total no. (%) of: No. of KPC-positive isolates/total (%) Hospitals Beds Isolates MβLR isolates KPC producers E. coli K. pneumoniaea P. aeruginosa A. baumannii Overall Puerto Rico Medical Center 6 858 2,472 354 180 19/32 (59)a 101/122 (83) 41/67 (61)a 19/133 (14) 180/354 (51) Metropolitan 3 906 2,371 196 72 8/52 (15) 39/59 (66) 18/46 (39) 7/39 (18) 72/196 (37) North 2 439 1,706 259 87 15/73 (21) 65/94 (69) 3/56 (5) 4/36 (11) 87/259 (34) West 2 324 1,316 95 43 1/13 (8) 26/38 (68) 15/27 (56)a 1/17 (6) 43/95 (45) South 2 593 1,299 176 86 15/35 (43)a 55/75 (73) 13/48 (27) 3/18 (17) 86/176 (49) Central/East 2 497 1,343 159 66 3/14 (21) 47/69 (68) 9/28 (32) 7/48 (15) 66/159 (42) Total 17 3,617 10,507 1,239/10,507 (12) 534/1,239 (43) 61/219 (28) 333/457(73) 99/272 (36) 41/291 (14) 534/1239 (43) ↵a P ≤ 0.05.
- Table 3.
Baseline clinical information on KPC-positive E. coli, K. pneumoniae K. pneumoniae, P. aeruginosa, and A. baumannii isolates
Organism Total no. of KPC-positive isolates No. of isolates from patients of following gender: No. of isolates from following hospital unit: No. of isolates from following anatomical site: Fa Mb NRc ICU General ward NR RTd,h UTe,h SSTf Blood Misc.g NR E. coli 61 26 35 0 13 44 4 9 23 12 10 7 0 K. pneumoniae 333 162 167 4 108 212 13 90 93 57 49 42 2 P. aeruginosa 99 46 50 3 28 71 0 35 22 18 10 13 1 A. baumannii 41 18 22 1 18 22 1 16 4 7 8 5 1 Total 534 252 274 8 167 349 18 150 142 94 77 67 4 - Table 4.
Total numbers and percentages of isolates susceptible to selected antibioticsa
Organism Total no. of KPC producers No. of isolates susceptible/total (%) Ceftriaxone Cefepime Imipenem Piperacillin-tazobactam Amikacin Ciprofloxacin ESBL K. pneumoniae 333 21/288 (7) 31/300 (10) 89/316 (28) 7/299 (2) 114/330 (35) 46/332 (14) 80/332 (24) E. coli 61 10/52 (19) 10/51 (20) 44/53 (83) 24/52 (46) 39/60 (65) 10/60 (17) 37/60 (62) P. aeruginosa 99 2/92 (2) 6/98 (6) 6/95 (6) 16/98 (16) 62/95 (59) 7/98 (7) NDb A. baumannii 41 0/40 (0) 0/40 (0) 11/33 (33) 2/34 (6) 4/41 (10) 0/41 (0) ND ↵a Data, including those on ESBL detection, are from the participating hospitals' antimicrobial susceptibility reports. The susceptibility breakpoints (μg/ml) for all isolates are as follows: ≤8, cefepime; ≤4, imipenem; ≤16, amikacin; ≤1, ciprofloxacin. The susceptibility breakpoints of ceftriaxone are ≤1 μg/ml for Enterobacteriaceae and ≤8 μg/ml for P. aeruginosa and A. baumannii. The susceptibility breakpoints (μg/ml) of ceftriaxone are ≤1 and ≤8 for the Enterobacteriaceae P. aeruginosa and A. baumannii. The susceptibility breakpoints (μg/ml) of piperacillin-tazobactam are ≤64 and 4 for P. aeruginosa and ≤16 and 4 for A. baumannii.
↵b ND, not done.
